Former Deutsche Bank Co-CEO Anshu Jain dies Anshu Jain, a fomer co-CEO of Deutsche Bank, has died, according to a statement by his family on Saturday The Independent UK · Aug 13, 2022
Trulieve Cannabis: A Top Pick Operator In A Small Pond? Analyst Offers Model Update Post 2Q22 The Analyst Pablo Zuanic from Cantor Fitzgerald maintained a rating of Overweight for the stocks of Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) and lowered its price target to $54 from $57, on “slightly reduced estimates.” Benzinga · Aug 10, 2022
Cantor Analayst Pablo Zuanic Believes SAFE Banking Now "The Worst Case Scenario" in 2022 In perhaps a sign that incremental progress on federal cannabis reform is afoot, some Wall Street analysts are increasingly coming around on the idea that reform can happen this year. Cantor Fitzgerald analyst Pablo Zuanic, a noted skeptic on SAFE Banking, now believes the legislation has a real chance of… Benzinga · Aug 3, 2022
Are Nasdaq-Traded Colombian Cannabis Stocks Worth Buying? Yes And No, Says Analyst Cantor Fitzgerald's analyst Pablo Zuanic initiated coverage on two cannabis companies on Monday: Flora Growth Corp. (NASDAQ: FLGC) and Clever Leaves Holdings Inc (NASDAQ: CLVR) Benzinga · Aug 1, 2022
Cannabis In New Jersey: How Did The Market Change Since Recreational Weed Was Legalized? On Thursday, Cantor Fitzgerald analyst Pablo Zuanic offered an update on New Jersey’s recreational cannabis market. Zuanic analyzed the competitive landscape and the changes in the recreational cannabis market in The Garden State. Although the report is not a second-quarter preview, the analyst offered an estimation of the evolution of… Benzinga · Jul 29, 2022
Cantor Fitzgerald Downgrades Ratings On 2 Canadian Cannabis Stocks To Neutral, Here's Why Cantor Fitzgerald analyst Pablo Zuanic downgraded his rating on two Canadian cannabis stocks, Auxly Cannabis Group Inc. Benzinga · Jul 25, 2022
This Analyst Is Bullish For Cannabis Stocks: Can Schumer's Bill Get 60 Votes In 'Holy Grail' Scenario? Cantor Fitzgerald analyst Pablo Zuanic doubts that the Cannabis Administration And Opportunity Act (CAOA) will get the 60 votes it needs in the Senate in order to pass due to Republican opposition. Benzinga · Jul 21, 2022
2Q Canada Recreational Cannabis Market Analysis: +21 YoY Growth Outperforming The U.S. In a recent analyst note, Cantor Fitzgerald's Pablo Zuanic gave an overview of the Canadian recreational cannabis market in the second quarter of 2022, according to data collected by Hifyre, a leading in-shop and online digital toolset for cannabis dispensaries. Benzinga · Jul 14, 2022
Cantor's Top Picks: Could Q2 Earnings Provide A Spark For These Cannabis Multi-State Operators? Multi-State Operators (MSO) traded higher on Tuesday after Cantor Fitzgerald categorized four companies as "top picks." In a recent industry report, Pablo Zuanic analyzed the context of MSOs and offered insight on trends driving financial value. Although MSOs ETF fell 25% in June and 49% over the last three months (vs. Benzinga · Jul 5, 2022
Read Why Cantor Upgraded Aurora Cannabis Stock Cantor Fitzgerald has upgraded Aurora Cannabis Inc (NASDAQ: ACB) to Overweight from Neutral Benzinga · Jun 24, 2022
Cantor Fitzgerald Maintains Neutral Rating for High Tide: Here's What You Need To Know Cantor Fitzgerald has decided to maintain its Neutral rating of High Tide (NASDAQ:HITI) and lower its price target from $7.00 to $4.45. Shares of High Tide are trading down 1.7% over the last 24 hours, at $2.02 per share. A move to $4.45 would account for a 120.82% increase from… Benzinga · Jun 16, 2022
High Tide: 'Continued Progress, But More Operational Leverage Needed,' Analyst Says The Analyst Pablo Zuanic from Cantor Fitzgerald remained ‘Neutral' on High Tide Inc. (NASDAQ: HITI) and lowered the stock 12-month price target to C$4.45 from C$7 “given overall sectoral derating.” Benzinga · Jun 15, 2022
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications ADC Therapeutics SA (NYSE:ADCT) presented updated efficacy and safety results from the Phase 2 trial of camidanlumab tesirine (Cami, formerly ADCT-301) in relapsed or refractory Hodgkin lymphoma. Cami demonstrated a 70.1% overall response rate (ORR), with a 33.3% complete response (CR) rate. From a safety perspective, eight of 117 patients developed Guillain-Barré syndrome… Benzinga · Jun 13, 2022
Benzinga · May 27, 2022 After A Challenging March Quarter Canopy Growth Projects Positive EBITDA By FY 2024 Pablo Zuanic from Cantor Fitzgerald kept a rating of “Neutral” for the stocks of Canopy Growth Corp. (TSE: WEED) (NASDAQ: CGC) and lowered his 12-month price target to C$6.75 from C$7.75 due to the sectoral derating and red
Benzinga · May 26, 2022 AYR Wellness: Management Expects 'Significant Sales' And 'EBITDA Ramp' In 2022 The Analyst Pablo Zuanic from Cantor Fitzgerald kept a rating of "Neutral" on Ayr Wellness Inc. (OTC: AYRWF) stocks and lowered its 12-month price target to $6.75 from $13.30, due to reduced estimates and overall sectoral derating.
Benzinga · May 18, 2022 Cresco Lab's 1Q Results After Conference Call, Analyst Opines The Analyst Following Cresco Labs’ (OTC: CRLBF) (CSE:CL) conference call, Pablo Zuanic, from Cantor Fitzgerald kept an "Overweight" rating and maintained a 12-month price target of $19.
Benzinga · May 16, 2022 Columbia Care: Challenging 1Q, Stock Is Now Tied to Cresco Deal Analyst Says The Analyst Pablo Zuanic, from Cantor Fitzgerald, rated Columbia Care Inc. (OTC: CCHWF) as Overweight with a price target of $5.10.
Benzinga · May 6, 2022 Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022 Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99.
Benzinga · Mar 31, 2022 Cantor Fitzgerald Lowers Price Target On Trulieve Post Earnings, Here's Why Trulieve Cannabis Corp.
Benzinga · Mar 23, 2022 Analyst On Cresco's Deal With Columbia Care And Earnings Results For Q4 2021 The Analyst: Pablo Zuanic, from Cantor Fitzgerald, rated Cresco Labs, Inc. (OTC: CRLBF) as Overweight with a price target of $19.00.
Benzinga · Mar 8, 2022 This Satellite Semiconductor Firm Looks To Go Public Via SPAC Merger With Endurance Bloomberg reports that satellite semiconductor provider SatixFy Communications Ltd agreed to go public via a special purpose acquisition company (SPAC) merger. SatixFy's deal with Endurance Acquisition Corp (NASDAQ:EDNC) will give the combined company a pro forma implied equity value of about $813 million. Israel-based SatixFy is a fabless semiconductor company providing products based on its own…
Benzinga · Mar 4, 2022 Cantor Fitzgerald Cuts ADC Therapeutics Price Target On 'Repositioned Zynlonta Pipeline Strategy' Following Q4 FY21 results, Cantor Fitzgerald has lowered the price target on ADC Therapeutics SA (NASDAQ: ADCT) to $26 from $45 and keeps an Overweight rating.
Benzinga · Feb 26, 2022 Brief Thoughts Ahead Of 4Q For Curaleaf Holdings: New Jersey Could Be Next Main Catalyst The Analyst Pablo Zuanic, from Cantor Fitzgerald, kept Curaleaf among the firm’s top picks in the MSO group, with an Overweight rating and a price target at US$16.50. The Thesis